U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H26N2O.CH4O3S
Molecular Weight 466.592
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SAVOXEPIN MESYLATE

SMILES

CS(O)(=O)=O.N#CC1=CC2=C(OC3=C(C=CC=C3)C4=C2CCN(CC5CCCC5)CC4)C=C1

InChI

InChIKey=PDYLRPIUJQGVNY-UHFFFAOYSA-N
InChI=1S/C25H26N2O.CH4O3S/c26-16-19-9-10-25-23(15-19)21-12-14-27(17-18-5-1-2-6-18)13-11-20(21)22-7-3-4-8-24(22)28-25;1-5(2,3)4/h3-4,7-10,15,18H,1-2,5-6,11-14,17H2;1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula C25H26N2O
Molecular Weight 370.4867
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Savoxepine (also known as cipazoxapine), a tetracyclic compound, possesses a potent neuroleptic-like effects. This compound acts via dopamine D(2)-receptor blockade. Savoxepine was studied in phase II clinical trials in Europe for the treatment of patients with psychotic disorders; however, these studied were discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
1987 May
Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET).
1993
Savoxepine fails to selectively influence glucose metabolism in the rat limbic system.
1994 Mar
Direct microtitre plate radioimmunoassay of savoxepine in unextracted plasma.
1996 Feb
Patents

Sample Use Guides

In an open pilot-study 18 patients suffering from acute schizophrenic psychoses or paranoid syndromes were treated with savoxepine in an individually adapted dose range from 0.50 to 10 mg per day
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:35:33 UTC 2023
Edited
by admin
on Fri Dec 15 15:35:33 UTC 2023
Record UNII
E4T7MA518S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SAVOXEPIN MESYLATE
Common Name English
1H-DIBENZ(2,3:6,7)OXEPINO(4,5-D)AZEPINE-7-CARBONITRILE, 3-(CYCLOPENTYLMETHYL)-2,3,4,5-TETRAHYDRO-, METHANESULFONATE (1:1)
Systematic Name English
SAVOXEPIN MESILATE
Common Name English
SAVOXEPINE MESYLATE
Common Name English
CGP-19486A
Code English
CGP 19486A
Code English
1H-DIBENZ(2,3:6,7)OXEPINO(4,5-D)AZEPINE-7-CARBONITRILE, 3-(CYCLOPENTYLMETHYL)-2,3,4,5-TETRAHYDRO-, MONOMETHANESULFONATE
Systematic Name English
Code System Code Type Description
CAS
79262-47-8
Created by admin on Fri Dec 15 15:35:33 UTC 2023 , Edited by admin on Fri Dec 15 15:35:33 UTC 2023
PRIMARY
EPA CompTox
DTXSID80229595
Created by admin on Fri Dec 15 15:35:33 UTC 2023 , Edited by admin on Fri Dec 15 15:35:33 UTC 2023
PRIMARY
FDA UNII
E4T7MA518S
Created by admin on Fri Dec 15 15:35:33 UTC 2023 , Edited by admin on Fri Dec 15 15:35:33 UTC 2023
PRIMARY
MESH
C052564
Created by admin on Fri Dec 15 15:35:33 UTC 2023 , Edited by admin on Fri Dec 15 15:35:33 UTC 2023
PRIMARY
PUBCHEM
71587288
Created by admin on Fri Dec 15 15:35:33 UTC 2023 , Edited by admin on Fri Dec 15 15:35:33 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY